2023 World Conference on Lung Cancer (Posters)-P1.21. Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI

P1.21. Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to investigate the potential use of serum glycoproteomics as a biomarker for predicting survival outcomes and immune-related adverse events (irAEs) in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI). The study analyzed 532 glycopeptides derived from 75 serum proteins in pretreatment blood samples from 61 individuals with unresectable NSCLC.<br /><br />The analysis identified 20 biomarkers, including 13 glycopeptides and 7 non-glycosylated peptides, that were strongly associated with overall survival (OS) or were selected using predictive modeling techniques. Based on the relative abundance of these biomarkers, the patients were clustered into two groups (Group A and Group B).<br /><br />The results showed that Group A had significantly inferior survival outcomes in terms of OS and progression-free survival (PFS) compared to Group B. This finding was consistent even when analyzing only the patients who received an ICI-containing regimen. Additionally, Group A had a trend towards a shorter duration between treatment initiation and the onset of the first irAE.<br /><br />A total of 43% of patients developed irAEs, with 11% experiencing grade 3 irAEs. Group A showed a trend towards a shorter duration between ICI-containing treatment initiation and the development of the first irAE of all grades.<br /><br />The study concludes that patients clustered based on a liquid biopsy-based glycoproteomic signature demonstrate differences in survival outcomes and irAE development. Further research with a larger validation set is warranted to develop a biomarker utilizing serum glycoproteomics to predict survival outcomes and irAE development in NSCLC patients treated with ICI.

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

serum glycoproteomics

biomarker

survival outcomes

immune-related adverse events

non-small cell lung cancer

immune checkpoint inhibitors

glycopeptides

non-glycosylated peptides

overall survival

progression-free survival